Regulatory PathRegulatory requirements compared

Active substances

Dutasteride + Tamsulosin

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
DUODART Capsule0.5,0.4 mg,mgCapsule, hard · Oral use30 Tablet ContainerSAR 103.60NCE · PrescriptionGlaxo Saudi Arabia LtdValid
Dusta plus0.5,0.4 mg,mgCapsule, hard · Oral use30 BottleSAR 90.45Generic · PrescriptionJazeera Pharmaceutical Industries (JPI)Valid
DUODART Capsule0.4, 0.5 mgCapsule, hard · Oral use90 Tablet ContainerSAR 388.50NCE · PrescriptionGlaxo Saudi Arabia LtdWithdrawn by MAH · Not Marketed
Indications — CHI Daman Drug Formulary

BENIGN PROSTATIC HYPERTROPHY

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
JALYN0.5MG;0.4MGcapsule · oralWAYLIS THERAPPrescription14 Jun 2010
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE0.5MG;0.4MGcapsule · oralZYDUS PHARMSPrescription24 May 2018
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE0.5MG;0.4MGcapsule · oralAUROBINDO PHARMAPrescription18 Jul 2024
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE0.5MG;0.4MGcapsule · oralPH HEALTHDiscontinued26 Feb 2014
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE0.5MG;0.4MGcapsule · oralACTAVIS LABS FL INCDiscontinued20 Nov 2015

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
JALYN023720100.5 MG; 0.4 MGCAPSULE (IMMEDIATE- AND EXTENDED-RELEASE · ORALGLAXOSMITHKLINE INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACDUTASTERIDE-TAMSULOSIN 0.5-0.4$1.97362per EA23 Sep 2026
NHS Drug TariffTamsulosin 400microgram / Dutasteride 500microgram capsules£4.3530 capsule1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.